Whenever the scientists come across any major discovery in the drug research and development, the biopharma industry witnesses a major change in the attitude of the leading market players. According to reports, the leading company Bristol-Myers Squibb Co (NYSE:BMY) is all set to follow the same path that others have followed in the past.
Insights on Issue:
The race among leading industry players like Bristol-Myers and Merck look to touch the newer level with the introduction of the new immune checkpoint inhibitors. If taken into consideration the reports published on a leading digital media channel covering biotechnology field, the revenues for the checkpoint inhibitors are all set to cross $30 billion mark. Its popularity among people is growing swiftly.
The last few years have brought a lot of negative messages for AstraZeneca, but it doesn’t want to continue in the same way. As per the reports, AstraZeneca is happy to see the recent changes in the industry and the pattern in which consumers tend to think. Roche Global Medical Affairs, the global brand in this industry have started following the trends like Bristol-Myers, but there is a long way to go before it finds the pace it always seeks.
Roche doesn’t want to reveal all of its moves right away as the management feels that the industry will show up better times in the future. Niko Andre, Head of Global Medical Affairs, Roche, recently announced the plans to conduct an 11 stage study on PD-L1 drug MPDL3280A. As soon as he announced his plans, Reuters and others highlighted the story and gave it more hype than it deserved.
One of the other candidates of the company Cathi Ahearn added that this new drug line would try to cure bladder and lung in the coming years. It will make sure that the cost of the drug remains within the reach of everyone.
